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Table 1
Summary of Total Joint Average Mankin Scores for Injected Knees in Healthy Doss Following Single IA Administration of Treatments as Listed
Treatment Group Micropheres
(mg/mL)
TCA (mg/mL) Time after single
IA injection
Number of dogs Total Joint Average
Maximum Score
Vechicle Direct 0 0 3 days 3 0.04
4 weeks 3 0
6 weeks 4 0
3 months 4 0
4 months 4 0
6 months 4 0
9 months 4 0
Black PLGA Microphores 75 0 3 days 3 0.04
4 weeks 3 0
6 weeks 4 0.035
3 months 4 0
4 months 4 0
6 months 4 0
9 months 4 0
TCA IR 0 18.75 3 days 3 0.29
4 weeks 3 1.61
6 weeks 4 1.5
3 months 4 1.5
4 months 4 0.665
6 months 4 0.75
9 months 4 0
FX006 Low Dose 8.33 2.1 3 days 3 0.25
4 weeks 3 1.46
6 weeks 4 1.75
3 months 4 1.25
4 moths 4 0.75
6 months 4 0.5
9 months 4 0
FX006 Mid Dose 25 6.25 3 days 3 0.165
4 weeks 3 1.665
6 weeks 4 1.415
3 months 4 0.665
4 months 4 1.415
6 months 4 0.665
9 months 4 0
FX006 High Dose 75 18.75 3 days 3 0.08
4 weeks 3 1.71
6 weeks 4 1.665
3 months 4 1.92
4 moths 4 1.75
6 months 4 0.835
9 months 4 1.25
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S464any time point. All treatments were very well tolerated. The loss in
extracellular GAGs in articular cartilage in normal joints in animals is a
known effect of TCA. However, in models of arthritis in the context of
inﬂamed joints, steroids have shown a beneﬁcial effect. FX006 has
similarly demonstrated the potential to slow disease progression in a
rat model.
Conclusions: A single IA dose of FX006 represents no new risk to joint
tissues relative to IA TCA IR injections despite prolonged exposure to
TCA. Overall, the systemic and local safety proﬁle of FX006 was similar
to that of TCA IR in nonclinical and clinical studies to date. FX006 was
well-tolerated and presents no new safety liabilities relative to TCA IR
which is approved for intra-articular injection and has been in use in
patients with OA for over 50 years.
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OSTEOCHONDRAL DEFECT
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Purpose:We are studying the cell- and pharmaco- therapy for cartilage
repair as well as the surgical bone marrow stimulation technique to
supply bone marrow mesenchymal stem cells (BMSCs) to repair
osteochondral defect. Recently, we showed that a cell populationinvolved in cartilage repair was supplied from the peripheral blood ﬂow
also, using a rat parabiosis model with GFP-transgenic and wild-type
rats. This result could help in the development of new therapeutic
strategies for cartilage repair. The systemic administration of G-CSF is a
candidate of that new therapy because G-CSF enhances peripheral
blood cells, moreover, could enhance BMSCs also via the neutrophils in
bone marrow, and might repair the cartilage defect with better quality
hyaline cartilage. The objective of this study is to assess the effect of G-
CSF on the repair of rat osteochondral defect.
Methods: Twenty-six 12-week-old male Lewis rats were randomly
divided into two groups. From day 0 to day 4, the G-CSF group received
glycosylated G-CSF subcutaneously, and the control group received
phosphate buffered saline instead. A 1.5-mm diameter and 1.0-mm
deep osteochondral defect was introduced in the patellar groove of the
bilateral femur in all rats on day 4. The peripheral blood nucleated cells
were counted for 14 days from day 0 to day 14 using a fully automatic
blood cell counter (Celltac a, MEK- 6258; Nihon Kohden, Tokyo, Japan).
The appearance of the cartilage repair was observed histologically,
using toluidine blue-stained sections, as well as macroscopically for 2, 4,
8, 12, and 24weeks after surgery, and was evaluated quantitatively with
the software KIPS_Ver091b (Kawasaki Heavy Industries, Ltd., Kobe
Japan) that can automatically recognize the presence of tissue and
distinguish the cartilage from other tissue areas. We analyzed the tissue
repair rate, deﬁned as the percentage of repaired osteochondral defects,
the cartilage repair rate, deﬁned as the percentage of cartilage defects
with metachromatic cartilage tissue, and modiﬁed Wakitani score, per
week. The data of two groups were compared using a Mann-Whitney U
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All P-values were 2-sided.
Results: The number of peripheral blood leukocytes started to increase
at day 3 and returned to normal levels at day 7 after the ﬁrst injection.
Moreover, histology showed the G-CSF group had more ﬁbrous and/or
bony tissue at earlier time point (Figure). The tissue repair rate was
signiﬁcantly higher in the G-CSF group 4 weeks after surgery. However,
the cartilage repair rate and modiﬁed Wakitani score were not sig-
niﬁcantly different between the two groups at each time point.
Conclusions: The defect ﬁlling was signiﬁcantly better in the G-CSF
group in the early phase. G-CSF could act as a promoting agent in the
repair of osteochondral defects by increasing the number of peripheral
blood nucleated cells. Better cartilage repair might be expected if the
higher number of peripheral blood nucleated cells could be maintained
for a longer time than that in our experiment.
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INTRA-ARTICULAR TREATMENT WITH RECOMBINANT HUMAN BONE
MORPHOGENETIC PROTEIN 7 (BMP-7) ATTENUATES THE
DEVELOPMENT OF OSTEOARTHRITIS IN A SURGICALLY INDUCED
RAT MODEL
J. Morko, Z. Peng, K.M. Fagerlund, Y. Konkol, J.P. Rissanen, J. Bernoulli,
J. Halleen. Pharmatest Services Ltd, Turku, Finland
Purpose: Several experimental animal models have been developed for
human osteoarthritis (OA) and used to study the preclinical efﬁcacy of
disease and symptom modifying OA drug candidates. One of these
candidates is recombinant human bone morphogenetic protein 7
(rhBMP-7). It is a bone-inducing agent used currently in clinical practice
to enhance bone formation in spinal fusions and during fracture repair.
In preclinical studies, rhBMP-7 has been shown to attenuate the
development of degenerative changes induced by anterior cruciate
ligament transection in rabbits and by excessive running in rats and to
repair cartilage damage in rabbits, goats, sheeps and dogs. In this study,
we characterized the effects of rhBMP-7 treatment on the development
of OA induced by medial meniscal tear (MMT) and medial collateral
ligament transection (MCLT) in rats.
Methods: The study was conducted using male Lewis rats (body
weight range 360-425 g). Unilateral OA was induced in their knee
joints by surgical MMT and MCLT operation. Treatment of animals was
started one week after the operation and continued once a week for 5
weeks. Animals were treated intra-articularly with rhBMP-7 at the
dose of 0.25 mg/wk and with vehicle at the dose of 0.05 ml/wk.
Treatment effects on body weight and OA symptoms were followed
during the study. Joint discomfort and pain were used as OA symp-
toms. They were determined as static weight bearing and static
mechanical allodynia and analyzed as hind paw weight distribution
using Incapacitance Tester and paw withdrawal threshold using von
Frey ﬁlaments, respectively. After 6 post-surgery weeks, animals were
terminated and treatment effects on knee joints were determined
histologically following the recommendations of the Osteoarthritis
Research Society International (OARSI) histopathology initiative. This
experimental protocol was approved by the national Animal Experi-
ment Board, Regional State Administrative Agency for Southern Fin-
land, H€ameenlinna, Finland.
Results: Body weight was decreased in operated animals and paw
weight bearing and paw withdrawal threshold were decreased in
operated hind limbs after the ﬁrst post-surgery week when compared
with non-operated control animals. This demonstrated the presence of
joint discomfort and pain in operated animals at the beginning of
treatment. Body weight, paw weight bearing and paw withdrawalthreshold were decreased in operated animals treated with vehicle also
after 3 post-surgery weeks. Intra-articular treatment with rhBMP-7 at
the dose of 0.25 mg/wk improved paw weight bearing and increased
paw withdrawal threshold when compared with vehicle. Microscopic
assessment of OA demonstrated from mild to marked degenerative
changes in the medial compartment of operated knee joints in animals
treated with vehicle. These degenerative changes included the loss of
chondrocytes, proteoglycans and collagen matrix from superﬁcial layer
down to tidemark in medial tibial plateau and the presence of large
osteophytes and moderate synovial inﬂammation. The loss of chon-
drocytes and collagen matrix was pronounced on the outer 1/3 of the
medial tibial plateau. Almost similar lesions were observed in the
middle 1/3 and less severe lesions in the inner 1/3 of the plateau. The
microscopic assessment of OA demonstrated from non-generation to
marked generative changes in operated animals treated with the intra-
articular rhBMP-7 dose of 0.25 mg/wk. Treatment with rhBMP-7
decreased the width of signiﬁcant cartilage degeneration in the medial
tibial plateau and reduced the severity of chondrocyte and collagen
matrix lesions in the middle and inner 1/3 of the plateau when com-
pared with vehicle.
Conclusions: This study characterized the effects of rhBMP-7 treatment
on the development of OA in the ratMMTþMCLTmodel used frequently
in the preclinical efﬁcacy studies of disease and symptommodifying OA
drug candidates. Intra-articular treatment with rhBMP-7 at the dose of
0.25 mg/wk decreased the width of signiﬁcant cartilage degeneration
and reduced the severity of chondrocyte and collagen matrix lesions
focally. These results indicated a chondroprotective activity for intra-
articular rhBMP-7 in the rat MMTþMCLT model and support the
development of rhBMP-7 as a potential drug candidate for human OA in
clinical trials.
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A REVIEW ON CURRENT ANIMAL MODELS OF OSTEOARTHRITIS
RESEARCH; PAVING THE WAY FOR THE DEVELOPMENT OF NOVEL
DISEASE-MODIFYING ANTI-OSTEOARTHRITIC AGENTS
E. Roohi, F. Hashemian. Islamic Azad Univ., Pharmaceutical Sci. Branch
(IAUPS), Clinical Pharmacy Dept., Tehran, Iran, Republic of Islamic
Purpose: Osteoarthritis (OA) is one of the most prevalent chronic
conditions worldwide. Pathogenesis of idiopathic OA has not yet
been fully understood. The time course of disease onset is slow and
disease progression is extremely variable. Therefore, the develop-
ment of OA is difﬁcult to study in humans, and animal models seem
to be invaluable research tools that enable the researchers not only to
further their understanding of disease pathogenesis but also to pave
the way for the development of novel therapeutic agents. The pres-
ent study aims to review available OA animal models and induction
mechanisms. Advantages and disadvantages of the species com-
monly used and OA induction methods will also be discussed in
detail.
Methods: The researchers reviewed available OA animal models and
induction mechanisms including intra-articular injections of enzymes,
and chemicals as well as surgical inductions of OA. Literature searches
were conducted on electronic databases, and the following MeSH
terms were used: Osteoarthritis animal models, Osteoarthritis Induc-
tion Mechanisms, Papain, Collagenase, Hyaluronidase, Monosodium
Iodoacetate, Anterior Cruciate Ligament Transection (ACLT), and
Meniscectomy.
Results: Enzymatically/ chemically induced OA models have found to
exhibit various effects on joint physiology. Papain and Monosodium
Iodoacetate have found to speciﬁcally alter chondrocyte metabolism
and induce signiﬁcant chondrocyte apoptosis and joint inﬂammation;
whereas, collagenase-induced models showed histological damages to
ligaments and tendons. However, some studies were skeptical regard-
ing the use of Monosodium Iodoacetate induction method for patho-
physiological studies of human OA. Cartilage degeneration in
collagenase-induced models is thought to be associated with the direct
ingestion of collagen in cartilage and the inﬂammatory reaction in the
joint tissue. However, studies suggested that genetic differences in the
composition of proteoglycans and arrangement of collagen ﬁbers may
inﬂuence the sensitivity of the cartilage. Surgically-induced animal
models (ACLT, and Meniscectomy) were found to be one of the most
widely used OA induction methods. In comparison with other OA
induction methods, surgically-induced OA showed a higher disease
onset and disease severity. Most studies reported sequential events of
